Microfluidic-derived docosahexaenoic acid liposomes for glioblastoma therapy
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
Glioblastoma (GBM) is the most prevalent malignant primary brain tumor and currently lacks an effective treatment. In this study, we utilized a microfluidic system to synthesize docosahexaenoic acid (DHA) liposomes for GBM therapy. DHA is an omega-3 (ω3) polyunsaturated fatty acid commonly found in human dietary consumption that has demonstrated potential in mitigating cancer development. The microfluidic device employed allowed for precise fine-tuning of the physicochemical properties of liposomes by adjusting the flow rate ratios, flow rates, and lipid concentrations. Three distinct-sized liposomes, ranging from 80 nm and 130 nm, were successfully internalized by GBM cells, and demonstrated the ability to reduce the viability of these cells. Furthermore, DHA liposomes proved significantly more efficient in triggering apoptotic pathways, through caspase-3-dependent mechanisms, in comparison to free DHA. Thus, the nanomedicine platform established in this study presents new opportunities in the development of liposome formulations incorporating ω3 fatty acids for cancer therapy.
| Media Type: |
Electronic Article |
|---|
| Year of Publication: |
2023 |
|---|---|
| Publication: |
2023 |
| Contained In: |
To Main Record - volume:53 |
|---|---|
| Contained In: |
Nanomedicine : nanotechnology, biology, and medicine - 53(2023) vom: 14. Aug., Seite 102704 |
| Language: |
English |
|---|
| Contributors: |
Mendanha, D [Author] |
|---|
| Links: |
|---|
| Keywords: |
Docosahexaenoic acid |
|---|
| Notes: |
Date Revised 23.08.2023 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.nano.2023.102704 |
|---|
| funding: |
|
|---|---|
| Supporting institution / Project title: |
|
| PPN (Catalogue-ID): |
NLM360892973 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360892973 | ||
| 003 | DE-627 | ||
| 005 | 20230824232152.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230816s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nano.2023.102704 |2 doi | |
| 028 | 5 | 2 | |a pubmed23n1452.xml |
| 035 | |a (DE-627)NLM360892973 | ||
| 035 | |a (NLM)37582426 | ||
| 035 | |a (PII)S1549-9634(23)00055-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mendanha, D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Microfluidic-derived docosahexaenoic acid liposomes for glioblastoma therapy |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Glioblastoma (GBM) is the most prevalent malignant primary brain tumor and currently lacks an effective treatment. In this study, we utilized a microfluidic system to synthesize docosahexaenoic acid (DHA) liposomes for GBM therapy. DHA is an omega-3 (ω3) polyunsaturated fatty acid commonly found in human dietary consumption that has demonstrated potential in mitigating cancer development. The microfluidic device employed allowed for precise fine-tuning of the physicochemical properties of liposomes by adjusting the flow rate ratios, flow rates, and lipid concentrations. Three distinct-sized liposomes, ranging from 80 nm and 130 nm, were successfully internalized by GBM cells, and demonstrated the ability to reduce the viability of these cells. Furthermore, DHA liposomes proved significantly more efficient in triggering apoptotic pathways, through caspase-3-dependent mechanisms, in comparison to free DHA. Thus, the nanomedicine platform established in this study presents new opportunities in the development of liposome formulations incorporating ω3 fatty acids for cancer therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Docosahexaenoic acid | |
| 650 | 4 | |a Glioblastoma | |
| 650 | 4 | |a Liposome | |
| 650 | 4 | |a Microfluidics | |
| 700 | 1 | |a Gimondi, S |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, B M |e verfasserin |4 aut | |
| 700 | 1 | |a Ferreira, H |e verfasserin |4 aut | |
| 700 | 1 | |a Neves, N M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine : nanotechnology, biology, and medicine |d 2005 |g 53(2023) vom: 14. Aug., Seite 102704 |w (DE-627)NLM000057614 |x 1549-9642 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2023 |g day:14 |g month:08 |g pages:102704 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nano.2023.102704 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 936 | u | w | |d 53 |j 2023 |b 14 |c 08 |h 102704 |
| 951 | |a AR | ||
| 952 | |d 53 |j 2023 |b 14 |c 08 |h 102704 | ||